niacin

Summary

Summary: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.

Top Publications

  1. pmc Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms
    Janet E Digby
    Department of Cardiovascular Medicine, John Radcliffe Hospital, and Sir William Dunn School of Pathology, University of Oxford, Oxford, OX3 9DU, UK
    Arterioscler Thromb Vasc Biol 32:669-76. 2012
  2. pmc Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
  3. pmc Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 121:1163-73. 2011
  4. ncbi Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes
    Zhi hong Wu
    Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan 410011, PR China
    Pharmacology 84:282-7. 2009
  5. pmc GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon
    Muthusamy Thangaraju
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, USA
    Cancer Res 69:2826-32. 2009
  6. ncbi Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    Eric Bruckert
    Department of Endocrinology, Pitie Salpetriere University Hospital, Pierre and Marie Curie University, 83 bd de l hopital, 75651, Paris, France
    Atherosclerosis 210:353-61. 2010
  7. ncbi The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
    Todd C Villines
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Am Coll Cardiol 55:2721-6. 2010
  8. doi Niacin inhibits vascular inflammation via the induction of heme oxygenase-1
    Ben J Wu
    Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, NSW, Australia, 2042
    Circulation 125:150-8. 2012
  9. ncbi Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 334:729-32. 2005
  10. doi Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA 90822, United States
    Atherosclerosis 202:68-75. 2009

Detail Information

Publications275 found, 100 shown here

  1. pmc Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms
    Janet E Digby
    Department of Cardiovascular Medicine, John Radcliffe Hospital, and Sir William Dunn School of Pathology, University of Oxford, Oxford, OX3 9DU, UK
    Arterioscler Thromb Vasc Biol 32:669-76. 2012
    ..We hypothesize that NA has the potential to act directly on monocytes to alter mediators of inflammation that may contribute to its antiatherogenic effects in vivo...
  2. pmc Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
    M John Chapman
    INSERM, UMR S939, Dyslipidemia, Inflammation and Atherosclerosis Research Unit, University Pierre and Marie Curie Paris 6, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 Boulevard de l hopital, Paris Cedex 13, France
    Eur Heart J 31:149-64. 2010
    ..e. statins, fibrates, and niacin, and compares their mechanisms of action with those of pharmacological agents under development which directly ..
  3. pmc Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
    J Clin Invest 121:1163-73. 2011
    Nicotinic acid (niacin) is a drug used to reduce the progression of atherosclerosis...
  4. ncbi Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes
    Zhi hong Wu
    Department of Cardiology, Second Xiangya Hospital, Central South University, Hunan 410011, PR China
    Pharmacology 84:282-7. 2009
    The mechanism by which niacin increases plasma levels of high-density lipoprotein cholesterol (HDL-C) is not clearly understood yet...
  5. pmc GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon
    Muthusamy Thangaraju
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia 30912, USA
    Cancer Res 69:2826-32. 2009
    ..These studies show that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon...
  6. ncbi Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
    Eric Bruckert
    Department of Endocrinology, Pitie Salpetriere University Hospital, Pierre and Marie Curie University, 83 bd de l hopital, 75651, Paris, France
    Atherosclerosis 210:353-61. 2010
    ....
  7. ncbi The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration
    Todd C Villines
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Am Coll Cardiol 55:2721-6. 2010
    ..This report describes the final results of the ARBITER 6-HALTS (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) trial...
  8. doi Niacin inhibits vascular inflammation via the induction of heme oxygenase-1
    Ben J Wu
    Lipid Research Group, The Heart Research Institute, 7 Eliza St, Newtown, NSW, Australia, 2042
    Circulation 125:150-8. 2012
    ..b>Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 ..
  9. ncbi Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A
    Youyan Zhang
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Biochem Biophys Res Commun 334:729-32. 2005
    A G-protein coupled receptor to niacin (nicotinic acid) was identified recently but the physiological/pharmacological role of the receptor remains poorly defined...
  10. doi Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA 90822, United States
    Atherosclerosis 202:68-75. 2009
    In pharmacological doses, nicotinic acid (niacin) reduces myocardial infarction, stroke and atherosclerosis. The beneficial effects of niacin on lipoproteins are thought to mediate these effects...
  11. ncbi Extended-release niacin or ezetimibe and carotid intima-media thickness
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, Washington, DC, USA
    N Engl J Med 361:2113-22. 2009
    ....
  12. pmc beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice
    Robert W Walters
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA
    J Clin Invest 119:1312-21. 2009
    ..Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia...
  13. ncbi Effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits
    Shui Ping Zhao
    Department of Cardiology, The Second Xiangya Hospital of Central South University, Middle Ren Min Road No 86, Changsha, Hunan 410011, PR China
    Int J Cardiol 124:172-8. 2008
    ..The aim of this study was to evaluate the effect of niacin on LXRalpha and PPARgamma expression and HDL-induced cholesterol efflux in adipocytes from hypercholesterolemic ..
  14. doi Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids
    Ben J Wu
    Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, New South Wales, Australia 2042
    Arterioscler Thromb Vasc Biol 30:968-75. 2010
    To determine if niacin can confer cardiovascular benefit by inhibiting vascular inflammation and improving endothelial function independent of changes in plasma lipid and lipoprotein levels.
  15. pmc Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom
    Atherosclerosis 209:89-95. 2010
    ....
  16. doi Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury
    Suresh Varma Penumathsa
    Molecular Cardiology and Angiogenesis Laboratory, Department of Surgery, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030 1110, USA
    Biochim Biophys Acta 1792:39-48. 2009
    ..We investigated the effect of niacin-bound chromium (NBC) during ischemia/reperfusion (IR) injury in streptozotocin induced diabetic rats...
  17. ncbi Molecular identification of high and low affinity receptors for nicotinic acid
    Alan Wise
    Department of 7TMR Systems Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom
    J Biol Chem 278:9869-74. 2003
    ..The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia...
  18. ncbi Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways
    Helen J Knowles
    Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Biochem Pharmacol 71:646-56. 2006
    HM74 and HM74a have been identified as receptors for niacin. HM74a mediates the pharmacological anti-lipolytic effects of niacin in adipocytes by reducing intracellular cyclic AMP (cAMP) and inhibiting release of free fatty acids into the ..
  19. ncbi Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats
    Sema Bolkent
    Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University, 34300 Cerrahpaşa, Istanbul, Turkey
    Biol Trace Elem Res 101:219-29. 2004
    Many studies have shown that niacin and Cr exert combined effects. Significant beneficial effects in serum lipid levels following Cr supplementation have been reported...
  20. doi Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
    Vummidi Giridhar Premkumar
    Department of Medical Biochemistry, DR A L M Post Graduate, Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, Tamil Nadu, India
    Br J Nutr 100:1179-82. 2008
    ..cancer patients were randomized to receive a daily supplement of 100 mg co-enzyme Q10, 10 mg riboflavin and 50 mg niacin (CoRN), one dosage per d along with 10 mg tamoxifen twice per d...
  21. pmc Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial
    Gregory C Shearer
    Sanford Research USD, University of South Dakota, Sioux Falls, SD, USA
    J Lipid Res 53:2429-35. 2012
    The metabolic syndrome includes both dyslipidemia and impaired vascular function. Because extended-release niacin (ERN) and prescription omega-3 acid ethyl-esters (P-OM3) independently improve these characteristics, we tested their ..
  22. ncbi Effects of dietary di(2-ethylhexyl)phthalate, a putative endocrine disrupter, on enzyme activities involved in the metabolism of tryptophan to niacin in rats
    Tsutomu Fukuwatari
    Laboratories of Food Science and Nutrition, Department of Life Style Studies, School of Human Cultures, The University of Shiga Prefecture, 2500 Hassaka cho, Hikone, Shiga, 522 8533, Japan
    Biochim Biophys Acta 1672:67-75. 2004
    We have reported that the conversion ratio of tryptophan to niacin increased with increasing dietary concentration of di(2-ethylhexyl)phthalate (DEHP); the conversion ratio was about 2...
  23. doi Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study
    Vasu Babu Ravi
    Research Studies, Rayalaseema University, Kurnool 518 002, India
    Biomed Chromatogr 26:1436-43. 2012
    ..and selective LC-MS/MS method has been developed and validated for quantification of the atorvastatin (AT) and niacin (NA) in 250 μL human plasma...
  24. pmc Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells
    Lin Hua Zhang
    Atherosclerosis Research Center, Veterans Affairs Healthcare System, Long Beach, CA, USA
    J Lipid Res 53:941-50. 2012
    ..b>Niacin is the most effective lipid-regulating agent clinically available to raise HDL...
  25. doi Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy
    Sajoscha A Sorrentino
    Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany
    Circulation 121:110-22. 2010
    ..Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL.
  26. pmc Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes
    Claudia A Benavente
    Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
    Free Radic Biol Med 44:527-37. 2008
    ..Removal of niacin from the cell culture medium allowed control of intracellular NAD...
  27. ncbi Adipokines and treatment with niacin
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, D 39120 Magdeburg, Germany
    Metabolism 55:1283-5. 2006
    ..Because adipose tissue is one site of action of the lipid-lowering drug niacin, we investigated whether niacin treatment would affect not only lipids but also adipokines...
  28. ncbi Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
    M C Cheung
    Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, School of Medicine, University of Washington, Seattle 98103, USA
    Arterioscler Thromb Vasc Biol 21:1320-6. 2001
    ..low HDL cholesterol (HDL-C) is to maximally increase the HDL-C to LDL-C ratio by combining lifestyle changes with niacin (N) plus a statin...
  29. ncbi Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Ou
    Erin D Michos
    The Johns Hopkins University School of Medicine, Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland 21287, USA
    J Am Coll Cardiol 59:2058-64. 2012
    ..Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, which compared combined niacin/simvastatin with simvastatin alone, failed to demonstrate an incremental benefit of niacin among patients with ..
  30. pmc Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2
    Allen J Taylor
    Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, NW, Building 2, Room 4A34, Washington, DC 20307 5001, USA
    Vasc Health Risk Manag 3:159-64. 2007
    We previously reported in a placebo-controlled study that extended-release niacin slowed the progression of carotid atherosclerosis when added to statin monotherapy...
  31. ncbi Langerhans cells release prostaglandin D2 in response to nicotinic acid
    Dominique Maciejewski-Lenoir
    Arena Pharmaceuticals Inc, San Diego, California 92121, USA
    J Invest Dermatol 126:2637-46. 2006
    ..These results suggest that nicotinic acid mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of PGD(2)...
  32. pmc Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
    Klaus G Parhofer
    Medical Department II Grosshadern, University of Munich, Germany
    Vasc Health Risk Manag 5:901-8. 2009
    ..b>Niacin (nicotinic acid) is an effective drug which increases the plasma concentration of high-density lipoprotein (HDL)-..
  33. doi Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease
    Jasleen K Duggal
    Chicago Medical School and Affiliated Hospitals, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
    J Cardiovasc Pharmacol Ther 15:158-66. 2010
    b>Niacin or nicotinic acid (vitamin B3) raises the levels of high-density lipoprotein cholesterol (HDL) by about 30% to 35%...
  34. ncbi Safety and toxicological evaluation of a novel niacin-bound chromium (III) complex
    Michael Shara
    Creighton University Medical Center, Omaha, NE, USA
    J Inorg Biochem 99:2161-83. 2005
    ..It also helps in energy production and increasing lean body mass. Niacin-bound chromium (NBC) is a unique form of bioavailable chromium that promotes healthy lipid profile...
  35. ncbi Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush
    C Daniel Meyers
    Long Beach Veterans Affairs Healthcare System, Long Beach, CA, United States
    Atherosclerosis 192:253-8. 2007
    ..shown to prevent cardiovascular disease, yet its widespread use is limited by the prostaglandin D2 (PGD2) mediated niacin flush...
  36. ncbi Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    S Shah
    Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Int J Clin Pract 64:727-38. 2010
    Co-administration of niacin with statin offers the potential for additional lipid management and cardiovascular risk reduction...
  37. ncbi Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study
    Justin M S Lee
    Department of Cardiovascular Medicine, University of Oxford and Oxford Centre for Clinical Magnetic Resonance Research OCMR, Oxford, United Kingdom
    J Am Coll Cardiol 54:1787-94. 2009
    ..Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function...
  38. doi Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study
    Ascan Warnholtz
    Department of Medicine II, Johannes Gutenberg University Mainz, Mainz, Germany
    Atherosclerosis 204:216-21. 2009
    ..Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C...
  39. ncbi Extended-release niacin raises adiponectin and leptin
    Sabine Westphal
    Institute of Clinical Chemistry, Magdeburg University Hospital, Leipziger Str 44, D 39120 Magdeburg, Germany
    Atherosclerosis 193:361-5. 2007
    The lipid-lowering drug niacin has attracted renewed interest because it raises HDL-cholesterol and because it has recently been found to slow down the progression of intima media thickness in patients with coronary heart disease...
  40. ncbi Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
    Shobha H Ganji
    Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, CA, USA
    J Lipid Res 45:1835-45. 2004
    b>Niacin is a widely used lipid-regulating agent in dyslipidemic patients. Previously, we have shown that niacin inhibits triacylglycerol synthesis...
  41. pmc Combined statin and niacin therapy remodels the high-density lipoprotein proteome
    Pattie S Green
    Department of Medicine, University of Washington, Seattle, WA, USA
    Circulation 118:1259-67. 2008
    ..We hypothesized that an intervention that increases HDL levels-combined statin and niacin therapy-might reverse these changes.
  42. ncbi Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
    M John Chapman
    Dyslipidemia, Inflammation and Atherosclerosis Research Unit, UMR S939, National Institute for Health and Medical Research INSERM, Hopital de la Pitie Salpetriere, Paris, France
    Pharmacol Ther 126:314-45. 2010
    ..In this context, there is renewed interest in pharmacotherapeutic strategies involving niacin and fibrates in monotherapy and in association with statins...
  43. ncbi Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    N Engl J Med 345:1583-92. 2001
    ..We studied simvastatin-niacin and antioxidant-vitamin therapy, alone and together, for cardiovascular protection in patients with coronary ..
  44. ncbi Nicotinic acid: pharmacological effects and mechanisms of action
    Andreas Gille
    Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
    Annu Rev Pharmacol Toxicol 48:79-106. 2008
    ....
  45. doi Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model
    Dean Papaliodis
    Department of Pharmacology and Experimental Therapeutics, Molecular Immunopharmacology and Drug Discovery Laboratory, Tufts University School of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    J Pharmacol Exp Ther 327:665-72. 2008
    b>Niacin lowers serum cholesterol, low-density lipoprotein, and triglycerides, and it raises high-density lipoprotein. However, most patients experience cutaneous warmth and vasodilation (flush)...
  46. pmc Chronic niacin overload may be involved in the increased prevalence of obesity in US children
    Da Li
    Institute of Basic Medical Sciences, Medical College, Dalian University, Dalian 116622, Liaoning Province, China
    World J Gastroenterol 16:2378-87. 2010
    To investigate nicotinamide's action on glucose metabolism, and the association between niacin consumption and obesity prevalence.
  47. doi Nicotinic acid and the prevention of coronary artery disease
    Janet E Digby
    Department of Cardiovascular Medicine, University of Oxford, Oxford, UK
    Curr Opin Lipidol 20:321-6. 2009
    ..at all levels of LDL cholesterol has, therefore, given renewed emphasis on the therapeutic potential of niacin. The purpose of this review is to evaluate advances in the elucidation of mechanisms by which nicotinic acid ..
  48. ncbi A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin
    Elaine L Jacobson
    Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, AZ 85724, USA
    Exp Dermatol 16:490-9. 2007
    ....
  49. ncbi Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview
    Sachin Kamal-Bahl
    Merck and Co, Inc, West Point, Pennsylvania, USA
    Clin Ther 31:130-40. 2009
    b>Niacin is highly effective at raising high-density lipoprotein cholesterol but remains underused because of the adverse event of flushing.
  50. doi Niacin stimulates adiponectin secretion through the GPR109A receptor
    Eric P Plaisance
    Department of Anatomy, Auburn University, Auburn, AL 36849, USA
    Am J Physiol Endocrinol Metab 296:E549-58. 2009
    b>Niacin (nicotinic acid) has recently been shown to increase serum adiponectin concentrations in men with the metabolic syndrome...
  51. ncbi Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients
    Daniela Muller
    Franz Volhard Clinic, Department of Nephrology and Hypertension, Medical Faculty of the Charite, HELIOS Klinikum Berlin, Berlin, Germany
    Clin J Am Soc Nephrol 2:1249-54. 2007
    ..Adverse effects complicate the use of drugs that are prescribed for phosphate control in dialysis patients. Alternative treatment options are needed...
  52. ncbi Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects
    Crystal A Gadegbeku
    Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
    Am J Hypertens 16:67-71. 2003
    ..The adjustment in vascular compliance may be an important factor in determining overall BP response to NA...
  53. ncbi Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome
    Shalini V Kaushik
    Department of Nutrition and Food Science, Auburn University, Auburn, AL 36849, USA
    Diabetes Metab Res Rev 25:427-34. 2009
    ..The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with ..
  54. pmc Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes
    Xiaoyu Li
    Institute for Translational Medicine and Therapeutics and Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
    Biochem Pharmacol 80:1450-7. 2010
    The niacin receptor GPR109A is a G(i)-protein-coupled receptor which mediates the effects of niacin on inhibiting intracellular triglyceride lipolysis in adipocytes...
  55. ncbi Optical coherence tomography findings in niacin maculopathy
    Hatem Marwan Dajani
    The School of Medicine, Oregon Health and Science University, and the Devers Eye Institute, Legacy Hospitals, Portland, OR 97239 4197, USA
    Can J Ophthalmol 41:197-200. 2006
    We present the case of 54-year-old male who developed bilateral cystoid macular thickening while taking 3 g of niacin per day, and we describe the optical coherence tomography (OCT) features of niacin (nicotinic acid) maculopathy.
  56. doi Increased total and high-molecular weight adiponectin after extended-release niacin
    Eric P Plaisance
    Department of Anatomy, Physiology and Pharmacology, Boshell Diabetes and Metabolic Diseases Research Program, Auburn University, Auburn, AL 36849, USA
    Metabolism 57:404-9. 2008
    b>Niacin has recently been shown to increase serum total concentrations of the adipocyte-derived protein adiponectin...
  57. ncbi Induction of differentiation in human promyelocytic leukemia HL-60 cell line by niacin-related compounds
    Keiko Iwata
    Laboratory of Molecular and Cellular Biology, Department of Life Science, Faculty of Bioresources, Mie University, Tsu, Mie 514 8507, Japan
    Biosci Biotechnol Biochem 67:1132-5. 2003
    Water-soluble vitamin, niacin, and its related compounds were examined for their differentiation-inducing activity in human promyelocytic leukemia cells (HL-60)...
  58. ncbi Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man
    Virpi Saareks
    Department of Pharmacological Sciences, University of Tampere, Finland
    Pharmacol Toxicol 90:338-42. 2002
    ....
  59. doi Niacin subsensitivity is associated with functional impairment in schizophrenia
    Erik Messamore
    Behavioral Health and Clinical Neurosciences Division, Portland VA Medical Center, Portland, OR 97239, USA
    Schizophr Res 137:180-4. 2012
    Sensitivity to the skin flush effect of niacin is reduced in a portion of patients with schizophrenia...
  60. doi Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial
    Mark S Nash
    Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
    Arch Phys Med Rehabil 92:399-410. 2011
    To test the safety, tolerance, and efficacy of extended-release niacin monotherapy on dyslipidemia in persons with chronic tetraplegia.
  61. doi Niacin promotes adipogenesis by reducing production of anti-adipogenic PGF2α through suppression of C/EBPβ-activated COX-2 expression
    Ko Fujimori
    Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, 4 20 1 Nasahara, Takatsuki, Osaka 569 1094, Japan
    Prostaglandins Other Lipid Mediat 94:96-103. 2011
    b>Niacin is converted to NAD and NADP in tissues, whose products are involved in a number of cellular processes; and it is associated with the regulation of adipogenesis...
  62. pmc Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline
    M C Morris
    Rush Institute for Healthy Aging, Centers for Disease Control and Prevention, Atlanta, GA, USA
    J Neurol Neurosurg Psychiatry 75:1093-9. 2004
    Dementia can be caused by severe niacin insufficiency, but it is unknown whether variation in intake of niacin in the usual diet is linked to neurodegenerative decline...
  63. doi Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials
    Martina Lukasova
    Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany
    Trends Pharmacol Sci 32:700-7. 2011
    Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis...
  64. ncbi Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol
    Peter P Toth
    Sterling Rock Falls Clinic, Sterling, IL 61081, USA
    Curr Med Res Opin 25:1355-63. 2009
    ..b>Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities...
  65. doi Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?
    John R Guyton
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Curr Opin Lipidol 21:372-7. 2010
    To summarize recent studies on combination regimens that employ a statin with added niacin, ezetimibe, and/or bile acid sequestrants, and to understand the implications of these studies for clinical practice.
  66. ncbi Water maze performance in young male Long-Evans rats is inversely affected by dietary intakes of niacin and may be linked to levels of the NAD+ metabolite cADPR
    Genevieve S Young
    Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1
    J Nutr 137:1050-7. 2007
    b>Niacin is converted in tissues to NAD(+), which is required for synthesis of the intracellular calcium signaling molecule cyclic ADP-ribose (cADPR)...
  67. doi Niacin toxicity resulting from urine drug test evasion
    Anne M Daul
    Department of Emergency Medicine, Carolinas Medical Center, Charlotte, North Carolina 28203, USA
    J Emerg Med 41:e65-8. 2011
    b>Niacin, a well-established agent for treating dyslipidemia, has been promoted on the Internet as a method for passing urine drug screening, although there are no data to support its use for this purpose...
  68. ncbi Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression
    Brett Lauring
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ 07065, USA
    Sci Transl Med 4:148ra115. 2012
    Nicotinic acid (niacin) induces beneficial changes in serum lipoproteins and has been associated with beneficial cardiovascular effects...
  69. ncbi Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
    Allen J Taylor
    Cardiovascular Research, Cardiology Service, Walter Reed Army Medical Center, 6900 Georgia Ave, NW, Bldg 2, Room 3L28, Washington, DC 20307 5001, USA
    Circulation 110:3512-7. 2004
    b>Niacin reduces coronary heart disease morbidity and mortality when taken either alone or in combination with statins; however, the incremental impact of adding niacin to background statin therapy is unknown.
  70. doi Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing
    Henri K Parson
    Division of Endocrinology and Metabolism, Department of Medicine, Strelitz Diabetes Center for Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, VA, USA
    J Diabetes 5:59-67. 2013
    Although niacin often has beneficial effects on the lipoprotein profile, flushing is an untoward effect associated with its use. Aspirin can only reduce the flushing response by 30-40%...
  71. pmc Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib
    Laurent Yvan-Charvet
    Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA
    Arterioscler Thromb Vasc Biol 30:1430-8. 2010
    To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated ..
  72. ncbi Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes
    J Pan
    Diabetes Research Center, Tustin, CA, USA
    Diabetes Obes Metab 4:255-61. 2002
    We tested the hypotheses that niacin is effective for the separate treatments of abnormalities of LDL particle size, HDL2 percentage and Lp(a) without potential negative effects on glycated haemoglobin.
  73. ncbi Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center Inc, Louisville, Kentucky, USA
    Clin Ther 31:115-22. 2009
    Dyslipidemia and high blood pressure are both major cardiovascular disease risk factors. Niacin is an effective lipid-altering agent that has been reported to reduce the risk of cardiovascular disease...
  74. doi Niacin status and treatment-related leukemogenesis
    James B Kirkland
    University of Guelph, Guelph, Ontario, Canada, N1G 2W1
    Mol Cancer Ther 8:725-32. 2009
    ..b>Niacin deficiency, which is common in cancer patients, causes dramatic genomic instability in bone marrow cells in an in ..
  75. ncbi Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure
    Kyu hyang Cho
    Division of Nephrology and Hypertension, University of California, Irvine, California, USA
    Am J Physiol Renal Physiol 297:F106-13. 2009
    ..b>Niacin is known to improve lipid metabolism and exert antioxidant/anti-inflammatory actions...
  76. ncbi Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X
    Harry G Preuss
    Department of Physiology, Georgetown University Medical Center, Washington, D C 20007, USA
    Ann N Y Acad Sci 957:250-9. 2002
    ..Accordingly, ingestion of niacin-bound chromium and natural antioxidants such as grape seed proanthocyanidin extract has been demonstrated to ..
  77. pmc High-affinity transporters for NAD+ precursors in Candida glabrata are regulated by Hst1 and induced in response to niacin limitation
    Biao Ma
    Department of Molecular Biology and Genetics, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205 2185, USA
    Mol Cell Biol 29:4067-79. 2009
    ..C. glabrata is a NAD(+) auxotroph, and its growth depends on the availability of niacin (environmental vitamin precursors of NAD(+))...
  78. ncbi Decreasing the oxidant stress from paraquat in isolated perfused rat lung using captopril and niacin
    Mahmoud Ghazi-Khansari
    Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P O Box 13145 784, Tehran, Iran
    Arch Toxicol 79:341-5. 2005
    The abilities of captopril and niacin to protect against the lung toxicity of paraquat (PQ) were studied...
  79. ncbi Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease
    Darbie Maccubbin
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 104:74-81. 2009
    b>Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g/day, but is underused due to flushing...
  80. ncbi Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists
    Ester Carballo-Jane
    Department of Pharmacology, Merck Research Laboratories, Rahway, NJ, USA
    J Pharmacol Toxicol Methods 56:308-16. 2007
    ..The rat and the dog have previously been used to study the antilipolytic effects of nicotinic acid, but no optimal vasodilatation model exits in either species...
  81. ncbi SIRT1 genetic variation and mortality in type 2 diabetes: interaction with smoking and dietary niacin
    M Carola Zillikens
    Department of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Free Radic Biol Med 46:836-41. 2009
    SIRT1 protects cells against oxidative stress and aging. Its activity may be modulated by dietary niacin (vitamin B3) intake...
  82. ncbi Biochemical assessment of niacin deficiency among carcinoid cancer patients
    Girish M Shah
    Laboratory for Skin Cancer Research, CHUL Research Center CHUQ, Faculty of Medicine, Laval University, Sainte Foy, Quebec, Canada
    Am J Gastroenterol 100:2307-14. 2005
    ..fraction of tryptophan catabolism, which should be directed along a pathway that allows partial conversion to niacin; hence, increased diversion of tryptophan toward serotonin could cause variable degrees of niacin deficiency in ..
  83. pmc Does nicotinic acid (niacin) lower blood pressure?
    H E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY40213, USA
    Int J Clin Pract 63:151-9. 2009
    Nicotinic acid (niacin) is a well-established treatment for dyslipidaemia - an important cardiovascular disease (CVD) risk factor. However, niacin may also reduce blood pressure (BP), which is another important CVD risk factor...
  84. ncbi Treatment with niacin lowers ADMA
    Sabine Westphal
    Atherosclerosis 184:448-50. 2006
  85. ncbi Niacin and carcinogenesis
    James B Kirkland
    Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada
    Nutr Cancer 46:110-8. 2003
    The dietary status of niacin (vitamin B3) has the potential to influence DNA repair, genomic stability, and the immune system, eventually having an impact on cancer risk, as well as the side effects of chemotherapy in the cancer patient...
  86. doi Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats
    N Niu
    Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China
    Mol Biol Rep 36:1275-81. 2009
    Combined treatment with niacin and chromium has been found to have a protective effect against oxidative damage to different tissues of hyperlipidemic rats. But its effects on vascular endothelial dysfunction are less clear...
  87. ncbi Postprandial triglyceride responses to aerobic exercise and extended-release niacin
    Eric P Plaisance
    Department of Kinesiology, Auburn University, Auburn, AL, USA
    Am J Clin Nutr 88:30-7. 2008
    Aerobic exercise and niacin are frequently used strategies for reducing serum triglycerides, and, yet, there is no information regarding the combined effects of these strategies on postprandial triglycerides.
  88. ncbi Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events
    Michael H Davidson
    Department of Preventive Cardiology, Rush Presbyterian St Luke s Medical Center, 1725 West Harrison Street, Chicago, IL 60612, USA
    Curr Atheroscler Rep 5:418-22. 2003
  89. ncbi Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
    Gloria S Rizakallah
    St Louis College of Pharmacy and Mercy Family Medicine, St Louis, MO USA
    J Fam Pract 54:265-8. 2005
  90. ncbi Niacin nutritional status in HIV type 1-positive children: preliminary data
    Marina Hjertquist Tremeschin
    Medical School of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Brazil
    J Pediatr Gastroenterol Nutr 44:629-33. 2007
    ..This study compared the nutritional status and the 24-hour urine excretion of N-methylnicotinamide between HIV-positive children and HIV-negative children who were or were not born of mothers with HIV-1 infection...
  91. ncbi Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease
    Anders G Olsson
    Department of Medicine and Health, Linkoping University, SE 58183 Linkoping, Sweden
    Expert Opin Pharmacother 11:1715-26. 2010
    ..The best drug available for that purpose is niacin. In addition to increasing HDL cholesterol and apolipoprotein A1, niacin decreases triglycerides, low-density ..
  92. pmc Niacin treatment of stroke increases synaptic plasticity and axon growth in rats
    Xu Cui
    Department of Neurology, Henry Ford Hospital, Detroit, Mich 48202, USA
    Stroke 41:2044-9. 2010
    b>Niacin is the most effective medication in current clinical use for increasing high-density lipoprotein cholesterol...
  93. pmc Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial
    Darbie Maccubbin
    Rhode Island Hospital, Division of Kidney Diseases and Hypertension, 593 Eddy Street, Providence, RI, 02903, USA
    Clin J Am Soc Nephrol 5:582-9. 2010
    b>Niacin administration lowers the marked hyperphosphatemia that is characteristic of renal failure...
  94. ncbi Niacin's role in the statin era
    Erica L Brooks
    Preventive Cardiology Center, Tufts Medical Center, Division of Cardiology, Department of Medicine, 800 Washington Street, Box 80, Boston, MA 02111, USA
    Expert Opin Pharmacother 11:2291-300. 2010
    The combination use of niacin and HMG Co-A reductases (statins) is increasing. While statin therapy reduces the risk of adverse cardiovascular events, additional therapies are needed to decrease event rates further...
  95. ncbi Niacin therapy in atherosclerosis
    C Daniel Meyers
    Endocrinology Section, VA Long Beach Healthcare System, Department of Medicine, University of California, Irvine, California, USA
    Curr Opin Lipidol 15:659-65. 2004
    Well designed, randomized, placebo-controlled studies show that niacin prevents cardiovascular disease and death...
  96. ncbi The effects of niacin on lipoprotein subclass distribution
    John M Morgan
    Thomas Jefferson University, Jefferson Heart Institute, Sidney Kimmel Laboratory for Preventive Medicine, 925 Chestnut Street, 1st Floor, Philadelphia, PA 19107, USA
    Prev Cardiol 7:182-7; quiz 188. 2004
    ..b>Niacin has long been known to improve concentrations of all major lipids and lipoproteins, but it also has consistently ..
  97. doi Niacin and laropiprant
    S Sanyal
    Division of Cardiology, Department of Medicine, Preventive Cardiology Center, Tufts Medical Center, Boston, MA 02111, USA
    Drugs Today (Barc) 46:371-8. 2010
    Nicotinic acid (niacin) is one of the oldest drugs used to treat dyslipidemia...
  98. doi Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects
    Eseng Lai
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Platelets 21:191-8. 2010
    Laropiprant (LRPT) has been shown to reduce flushing symptoms induced by niacin and has been combined with niacin for treatment of dyslipidemia...
  99. pmc Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
    The use of niacin to improve plasma lipid levels and reduce risk of myocardial infarction is limited by noxious skin effects that result from stimulation of G protein-coupled receptor 109A (GPR109A) in skin immune cells...
  100. ncbi Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels
    David M Capuzzi
    Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Am J Cardiol 91:1304-10. 2003
    ..and low high-density lipoprotein (HDL) cholesterol levels may benefit from combination therapy with a statin and niacin; therefore, we assessed the efficacy and safety of rosuvastatin and extended-release (ER) niacin alone and in ..

Research Grants71

  1. Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis
    Emmanouil Brilakis; Fiscal Year: 2010
    ..b>Niacin raises HDL-C, restores the re-endothelialization capacity of EPCs, and slowed the progression of SVG ..
  2. CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
    George Timothy Bowden; Fiscal Year: 2012
    ..abstract_text> ..
  3. CHEMOPREVENTION OF SKIN CANCER PROGRAM PROJECT
    George Timothy Bowden; Fiscal Year: 2012
    ..abstract_text> ..
  4. DOES ATHEROSCLEROSIS REGRESS WITH THERAPY FOR LOW HDLC?
    Bruce Brown; Fiscal Year: 2000
    ..o.) and women (less than 67 y.o.) to double-blinded therapy, assigned in a factorial design: 1) mid-dose niacin (500 mg qid), plus simvastatin (20 mg qd); 2) an antioxidant cocktail (vitamin C (500 mg bid), E (400 IU bid), and ..
  5. Aromatic amino acid metabolism in the pathogenesis of kwashiorkor
    Farook Jahoor; Fiscal Year: 2006
    ..are precursors for dopamine, melanin and the catecholamines, and tryptophan is the precursor of serotonin and niacin, a shortage of the AAAs may underlie most of the signs and symptoms of kwashiorkor...
  6. Aromatic amino acid metabolism in the pathogenesis of kwashiorkor
    Farook Jahoor; Fiscal Year: 2007
    ..are precursors for dopamine, melanin and the catecholamines, and tryptophan is the precursor of serotonin and niacin, a shortage of the AAAs may underlie most of the signs and symptoms of kwashiorkor...
  7. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2001
    ..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
  8. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2004
    ..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
  9. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2002
    ..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
  10. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2003
    ..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
  11. LIPOGENESIS & LIPOPROTEIN COMPLICATIONS OF HIV THERAPY
    David Hui; Fiscal Year: 2000
    ..The potential beneficial effects of niacin, due to its proteasome-independent stimulation of apoB degradation, will also be explored...
  12. Phospholipid-Arachidonate-Eicosanoid Signaling in Schizophrenia
    Jeffrey Yao; Fiscal Year: 2009
    ..Further, we propose that phospholipid-arachidonate-eicosanoid (PAE) signaling abnormalities are responsible for niacin subsensitivity (the reduced sensitivity to the skin flush effect of niacin), which is among the most widely-..
  13. FUNCTIONAL CHARACTERISTICS OF THE LEFT HEART
    HAROLD DODGE; Fiscal Year: 1990
    ..natural history of coronary atherosclerotic lesions and the effect of serum lipid lowering with colestepol plus niacin or mevinolin and also cholestyramine on the rate of lesion progression...
  14. RESEARCH CENTER FOR PHARMACOLOGY AND DRUG TOXICOLOGY
    John Oates; Fiscal Year: 1993
    ..Research by Center investigators has provided completely new insights into the pharmacology of niacin, the effective use of which in the treatment of hyperlipidemia is limited substantially by adverse effects...
  15. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie Brouillette; Fiscal Year: 2006
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  16. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie Brouillette; Fiscal Year: 2007
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  17. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie Brouillette; Fiscal Year: 2009
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  18. Discovery and Preclinical Development of Drugs for Anthrax, Plague and Tularemia
    Christie G Brouillette; Fiscal Year: 2010
    ..These diseases are caused by three of the highest risk bacterial bioterrorism agents, B. anthracis, Y. pestis, and F. tularensis. ..
  19. Metabolic Disposition Of Cyclopentenone Eicosanoids
    L Roberts; Fiscal Year: 2001
    ..which is associated with a marked overproduction of PGD2 and in normal volunteers following administration of niacin, which induces a release of prodigious quantities of PGD2...
  20. Comprehensive Magnetic Resonance in PAD
    Christopher Kramer; Fiscal Year: 2009
    ..Aim 3 is to use comprehensive MR to test the efficacy of raising HDL with a novel formulation of niacin with laropiprant that reduces flushing compared to placebo in mild to moderate PAD...
  21. Comprehensive Magnetic Resonance in PAD
    Christopher M Kramer; Fiscal Year: 2010
    ..Aim 3 is to use comprehensive MR to test the efficacy of raising HDL with a novel formulation of niacin with laropiprant that reduces flushing compared to placebo in mild to moderate PAD...
  22. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2000
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  23. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 1999
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  24. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2001
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  25. OMEGA-3 FATTY ACIDS IN BIPOLAR DISORDER PROPHYLAXIS
    ANDREW STOLL; Fiscal Year: 2002
    ..Plasma and erythrocyte fatty acid content. 2. The niacin skin patch test (a possible marker of in vivo omega-3 fatty acid activity). 3...
  26. BIOSYNTHESIS OF VITAMIN B1 AND VITAMIN B6
    IAN SPENSER; Fiscal Year: 2000
    ..coli, since other Vitamins (e.g., thiamin, niacin) have distinct modes of origin in prokaryotes and eukaryotes...
  27. BIOSYNTHESIS OF VITAMIN B1 AND VITAMIN B6
    IAN SPENSER; Fiscal Year: 1999
    ..coli, since other Vitamins (e.g., thiamin, niacin) have distinct modes of origin in prokaryotes and eukaryotes...
  28. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2000
    ..in studies of Ga1E will be to describe the molecular basis for the enhancement of the chemical reactivity of the niacin- co-enzyme NAD+ by the use of binding energy between the UDP-moiety of substrates and the enzyme...
  29. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 1999
    ..in studies of Ga1E will be to describe the molecular basis for the enhancement of the chemical reactivity of the niacin- co-enzyme NAD+ by the use of binding energy between the UDP-moiety of substrates and the enzyme...
  30. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2002
    ..in studies of Ga1E will be to describe the molecular basis for the enhancement of the chemical reactivity of the niacin- co-enzyme NAD+ by the use of binding energy between the UDP-moiety of substrates and the enzyme...
  31. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2001
    ..in studies of Ga1E will be to describe the molecular basis for the enhancement of the chemical reactivity of the niacin- co-enzyme NAD+ by the use of binding energy between the UDP-moiety of substrates and the enzyme...
  32. PROCESSING OF NUTRITIONAL ASPECTS OF BREAST MILK
    KHEM SHAHANI; Fiscal Year: 1980
    ..to the effects of slow freezing, quick freezing and freeze dehydration and storage upon certin B vitamins (niacin, biotin and pantothenic acid), enzymes such as protease, lysozyme, lipase and lactoperoxidase, and several lipid ..
  33. SIMVASTATIN APOB TURNOVER IN DIABETES
    Henry Ginsberg; Fiscal Year: 2000
    ..Treatment of diabetic dyslipidemia has often required two drugs, a statin to lower LDL-C and a second drug, either niacin or Lopid, targeted a triglycerides and HDL-C. These drug combinations raise the risk of adverse effects...
  34. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 1999
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  35. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 2000
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  36. HDL AND PLAQUES--NOVEL MODELS AND IMAGING TECHNIQUES
    Edward Fisher; Fiscal Year: 2001
    ..Plasma lipid levels will be modified by therapy with a statin or statin plus niacin (to raise HDL) and changes in plaque size and composition will be followed serially by MRI...
  37. Niacin therapy to improve endothelial function in Sickle Cell Disease
    Naomi Luban; Fiscal Year: 2009
    ..We propose a forearm blood flow physiology study with Niaspan, a slow release form of niacin, previously reported to increase high density lipoprotein (HDL) and apo A-l levels...
  38. Niacin therapy to improve endothelial function in Sickle Cell Disease
    Naomi Luban; Fiscal Year: 2009
    ..We propose a forearm blood flow physiology study with Niaspan, a slow release form of niacin, previously reported to increase high density lipoprotein (HDL) and apo A-l levels...
  39. Niacin therapy to improve endothelial function in Sickle Cell Disease
    NAOMI L LUBAN; Fiscal Year: 2009
    ..We propose a forearm blood flow physiology study with Niaspan, a slow release form of niacin, previously reported to increase high density lipoprotein (HDL) and apo A-l levels...
  40. Niacin therapy to improve endothelial function in Sickle Cell Disease
    NAOMI L LUBAN; Fiscal Year: 2011
    ..We propose a forearm blood flow physiology study with Niaspan, a slow release form of niacin, previously reported to increase high density lipoprotein (HDL) and apo A-l levels...
  41. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2005
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  42. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2006
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  43. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2006
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  44. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2004
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  45. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2003
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  46. Niacin, n-3 fatty acids and insulin resistance
    William Harris; Fiscal Year: 2007
    ..In recent studies from our laboratory, niacin and fish oil (n-3 fatty acids, FA) used in combination in individuals with the IRS improved the lipid phenotype, ..
  47. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 2002
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  48. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 1999
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  49. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 2001
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  50. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 2000
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  51. MODE OF ACTION OF PYRAZINAMIDE IN TUBERCLE BACILLUS
    Ying Zhang; Fiscal Year: 2003
    ..Because of structural similarity of POA to niacin, they hypothesize that POA may interfere with NAD metabolism in M...
  52. A Transdermal Hypolipidemic Niacin Prodrug
    Hyuntae Kim; Fiscal Year: 2002
    b>Niacin has been used as first-line drug therapy for elevated serum cholesterol because of its broad efficacy on multiple lipid components as well as its low cost...
  53. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher Duggan; Fiscal Year: 2009
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  54. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2007
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  55. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2003
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  56. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2007
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  57. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2004
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  58. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2005
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  59. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher Duggan; Fiscal Year: 2006
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  60. Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy
    Ashok Balasubramanyam; Fiscal Year: 2006
    ..fat mass and improve hormonal, metabolic and lipoprotein markers associated with insulin resistance; and 2) adding niacin, fenofibrate, or a combination of the two drugs to the intensive lifestyle intervention will result in further ..
  61. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher P Duggan; Fiscal Year: 2010
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  62. A Trial of Zinc and Micronutrients in Tanzanian Children
    Christopher Duggan; Fiscal Year: 2007
    ..be recruited and randomly assigned in a factorial design to either zinc, micronutrients (vitamins C, E, B1, B2, niacin, B6, folate, and B12) plus zinc, micronutrients without zinc, or a placebo given daily...
  63. Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
    KEVIN O BRIEN; Fiscal Year: 2009
    ..changes in HDL that are associated with impairment of its normal function but that are improved with statin+niacin therapy...
  64. Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
    Mohammad Khan; Fiscal Year: 2007
    ..If successful, this approach potentially could be immediately extended for clinical applications. [unreadable] [unreadable] [unreadable]..
  65. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2005
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  66. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2006
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  67. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2004
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  68. SYNTHETIC MACROCYCLES AS ENZYMATIC REDOX MIMICS
    GEORGE NEWKOME; Fiscal Year: 1980
    ..In all cases, the yields were remarkably high and were a direct result of metal templation. Inclusion of potassium ion was favored with the homo 18-crown-6-analog. Numerous X-ray analyses of selected macrocycles were conducted. ..
  69. MECHANISMS OF ENZYMATIC REACTIONS
    PERRY FREY; Fiscal Year: 2003
    ..of epimerase will be to elucidate the molecular basis for the enhancement of the chemical reactivity of the niacin-coenzyme NAD+ by the use of binding energy between substrates and the enzyme...
  70. EVALUATING CORONARY LESION CHARGES USING NEURAL NETWORKS
    Stanley Azen; Fiscal Year: 1992
    CLAS, a randomized, controlled clinical trial testing niacin/colestipol plus diet therapy in non-smoking men with previous coronary bypass surgery, has demonstrated treatment benefits using both a) a coronary endpoint determination by a ..
  71. Monitoring Oxygen Repeatedly for Hypoxic Tumor Therapy
    Mohammad Khan; Fiscal Year: 2006
    ..If successful, this approach potentially could be immediately extended for clinical applications. [unreadable] [unreadable] [unreadable]..